Classification Systems for Acute Kidney Injury

Background

Acute kidney injury (AKI), formally called acute renal failure (ARF), is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waist products measured by blood urea nitrogen (BUN) and serum creatinine over the course of hours to weeks. The vague nature of this definition has historically made epidemiologic study on and around AKI difficult to generalize to patient populations and compare between scholarly works. Several classification systems were developed to streamline research and clinical practice with respect to AKI.[1, 2, 3, 4] For more information, see Acute Kidney Injury and Acute Tubular Necrosis.

RIFLE Classification

In 2002, the Acute Dialysis Quality Initiative (ADQI) was created with the primary goal of developing consensus and evidence-based guidelines for the treatment and prevention of acute kidney injury (AKI). The first order of business was to create a uniform, accepted definition of AKI; hence, the RIFLE criteria were born (see the table below). RIFLE is an acronym of Risk, Injury, and Failure; and Loss; and End-stage kidney disease. Table 1. RIFLE Classification System for Acute Kidney Injury[5]

<table>
<thead>
<tr>
<th>Stage</th>
<th>GFR&lt;sup&gt;a&lt;/sup&gt; Criteria</th>
<th>UO&lt;sup&gt;b&lt;/sup&gt; Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk</td>
<td>SCR increased 1.5-2 times baseline</td>
<td>UO &lt; 0.5 mL/kg/h &lt; 6 h</td>
</tr>
<tr>
<td></td>
<td>or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GFR decreased &gt;25%</td>
<td></td>
</tr>
<tr>
<td>Injury</td>
<td>SCR increased 2-3 times baseline</td>
<td>UO &lt; 0.5 mL/kg/h &gt;12 h</td>
</tr>
</tbody>
</table>
or

GFR decreased >50%

<table>
<thead>
<tr>
<th>Failure</th>
<th>SCr increased &gt;3 times baseline</th>
<th>UO &lt; 0.3 mL/kg/h 24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>or</td>
<td>(oliguria)</td>
</tr>
<tr>
<td></td>
<td>GFR decreased 75%</td>
<td>or</td>
</tr>
<tr>
<td></td>
<td>or</td>
<td>anuria 12 h</td>
</tr>
<tr>
<td></td>
<td>SCr ≥4 mg/dL; acute rise ≥0.5 mg/dL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Loss of function</th>
<th>Persistent acute renal failure: complete loss of kidney function &gt;4 wk (requiring dialysis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESRDd</td>
<td>Complete loss of kidney function &gt;3 mo (requiring dialysis)</td>
</tr>
</tbody>
</table>

a GFR = glomerular filtration rate.

b UO = urine output.

c SCr = serum creatinine.

d ESRD = end-stage renal disease.

Note: Patients can be classified either by GFR criteria or by UO criteria. The criteria that support the most severe classification should be used. The superimposition of acute on chronic failure is indicated with the designation RIFLE-F<sub>C</sub>; failure is present in such cases even if the increase in SCr is less than 3-fold, provided that the new SCr is greater than 4 mg/dL (350 µmol/L) and results from an acute increase of at least 0.5 mg/dL (44 µmol/L).

When the failure classification is achieved by UO criteria, the designation of RIFLE-F<sub>O</sub> is used to denote oliguria.
The initial stage, “risk,” has high sensitivity; more patients are classified in this mild category, including some who do not actually have renal failure. Progression through the increasingly severe stages of RIFLE is marked by decreasing sensitivity and increasing specificity.

**Acute Kidney Injury Network**

In September 2004, the Acute Kidney Injury Network (AKIN) was formed. AKIN advised that the term acute kidney injury (AKI) be used to represent the full spectrum of renal injury, from mild to severe, with the latter having increased likelihood for unfavorable outcomes (eg, loss of function and end-stage renal disease [ESRD]).\[6\]

A report by the AKIN proposed the following criteria for AKI\[6, 7\]:

- Abrupt (within 48 h) reduction in kidney function currently defined as an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.4 µmol/L) or
- A percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) or
- A reduction in urine output (documented oliguria of < 0.5 mL/kg/h for >6 h)

The AKIN criteria differ from the RIFLE criteria in several ways. The RIFLE criteria are defined as changes within 7 days, while the AKIN criteria suggest using 48 hours. The AKIN classification includes less severe injury in the criteria and AKIN also avoids using the glomerular filtration rate as a marker in AKI, as there is no dependable way to measure glomerular filtration rate and estimated glomerular filtration rate are unreliable in AKI.

AKIN notes that the diagnostic criteria proposed only after volume status has been optimized and urinary tract obstructions must be excluded when using oliguria as diagnostic criteria.

**KDIGO Clinical Practice Guidelines**

In 2012 the Kidney Disease Improving Global Outcomes (KDIGO) released their clinical practice guidelines for acute kidney injury (AKI), which build off of the RIFLE criteria and the AKIN criteria.\[8\]

KDIGO defines AKI as any of the following:

- Increase in serum creatinine by 0.3mg/dL or more within 48 hours or
- Increase in serum creatinine to 1.5 times baseline or more within the last 7 days or
- Urine output less than 0.5 mL/kg/h for 6 hours

The KDIGO has also recommended a staging system for the severity of the AKI.

The KDIGO consensus classification has yet to be validated.

**Table 2. KDIGO Staging for AKI Severity** (Open Table in a new window)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Serum Creatinine</th>
<th>Urine Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.5-1.9 times baseline</td>
<td>&lt; 0.5 mL/kg/h for 6 h</td>
</tr>
</tbody>
</table>

or

≥0.3 mg/dL increase
<table>
<thead>
<tr>
<th>Level</th>
<th>Definition</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>2-2.9 times baseline</td>
<td>$&lt; 0.5 \text{mL/kg/h for 12 h}$</td>
</tr>
<tr>
<td>3</td>
<td>3 times baseline</td>
<td>$&lt; 0.3 \text{mL/kg/h for 24 h}$ or Increase in serum creatinine to $\geq 4 \text{mg/dL}$ or Anuria for $\geq 12 \text{h}$ or Initiation of renal replacement therapy</td>
</tr>
</tbody>
</table>

**Contributor Information and Disclosures**

**Author**

**Piper Julie Hughes, MD, MS**  Resident Physician, Department of Internal Medicine, Vidant Medical Center

Piper Julie Hughes, MD, MS is a member of the following medical societies: American College of Physicians and American Medical Association

Disclosure: Nothing to disclose.

**Coauthor(s)**

**Tejas Desai, MD**  Assistant Professor of Medicine, Division of Nephrology and Hypertension, Associate Program Director, Internal Medicine Residency Program, East Carolina University Brody School of Medicine, Greenville, NC; Founder and Editor-in-Chief, Nephrology-On-Demand

Tejas Desai, MD is a member of the following medical societies: American College of Physicians and American Society of Nephrology

Disclosure: Nothing to disclose.

**Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF**  Clinical Professor of Medicine, Section of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine; Research Director, Internal Medicine Training Program, Advocate Christ Medical Center; Consulting Staff, Associates in Nephrology, SC

Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF is a member of the following medical societies: American Heart Association, American Medical Association, American Society of Hypertension, American Society of Nephrology, Chicago Medical Society, Illinois State Medical Society, National Kidney Foundation, and Society of General Internal Medicine

Disclosure: Nothing to disclose.
Vecihi Batuman, MD, FACP, FASN  Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN, is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

Additional Contributors

Mahendra Agraharkar, MD, MBBS, FACP, FASN  Clinical Associate Professor of Medicine, Baylor College of Medicine; President and CEO, Space City Associates of Nephrology

Mahendra Agraharkar, MD, MBBS, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Nephrology, and National Kidney Foundation

Disclosure: South Shore DaVita Dialysis Center Ownership interest/Medical Directorship Other; Space City Dialysis /American Renal Associates Ownership/Medical Directorship Same; US Renal Care Ownership interest Other

George R Aronoff, MD  Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

F John Gennari, MD  Associate Chair for Academic Affairs, Robert F and Genevieve B Patrick Professor, Department of Medicine, University of Vermont College of Medicine

F John Gennari, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Clinical Investigation, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

Brent Kelly MD  Assistant Professor, Department of Dermatology, University of Texas Medical Branch, Galveston, Texas

Brent Kelly is a member of the following medical societies: Alpha Omega Alpha and American Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References


2. Hui WF, Chan WK, Miu TY. Acute kidney injury in the paediatric intensive care unit: identification by


Medscape Reference © 2011 WebMD, LLC